On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

High Lipoprotein (a) is a genetic condition that increases the risk of early heart attacks and strokes. It is one of the most common genetic risk factors for cardiovascular disease, yet it remains ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

Swedish researchers have identified genetic variants that increase the risk of atherosclerosis. The aim is for these new ...

Swedish researchers have identified genetic variants that increase the risk of atherosclerosis. The aim is for these new findings to enable earlier detection of atherosclerosis and improved treatment ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

Congenital heart disease (CHD) is one of the most common birth defects, but the full extent of its genetic underpinnings has ...

CINCINNATI (WKRC) — A pioneering screening trial, recently announced at the Bethesda Lyceum, aims to transform community health by providing free genetic testing to 100,000 people. The trial ...